A Multidrug-resistant (MDR) and Extensively Drug- Resistant (XDR) Tuberculosis Study in Alsace

University Hospital, Strasbourg, France22 enrolled

Overview

The purpose of this study is to examine the epidemiology of TB MR in Strasbourg and evaluate the second-line anti-tuberculosis treatments effectiveness, and the relevance and adequacy of the treatments with WHO recommendations. During years 2006-2016, all new cases of MDR TB or XDR TB diagnosed Strasbourg University Hospital will be included in the study (22 cases). Data were collected from the Center for Tuberculosis Control (CLAT) records, the patient's medical records.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Tuberculosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Major patient (≥18 years old) * Patient hospitalized at Strasbourg University Hospital from 2006 to 2016, with proven MDR or XDR tuberculosis Exclusion Criteria: \- Refusal of the patient to participate in the study

Locations (1)

Service de Maladies Infectieuses et Tropicales

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Study of clinical characteristics of patients hospitalized at Strasbourg University Hospital from 2006 to 2016, with proven MDR or XDR tuberculosis

Time frame: The period from January 1st, 2006 to December 31st, 2016 will be examined

Central Contacts

Xavier ARGEMI, MD

CONTACT

33 3 69 55 11 87 xavier.argemi@chru-strasbourg.fr

Magalie Paz, MD

CONTACT

33 3 69 55 11 87 magalie.paz@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.